Global Chronic Obstructive Pulmonary Disease Drugs Market Growth of 4.85% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Merck, Almirall, Novartis - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020" report to their offering.

The global chronic obstructive pulmonary disease (COPD) drugs market is forecast to grow at a CAGR of 4.85% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.

The report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts.

Questions Answered:

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

Companies Mentioned Include:

  • AstraZeneca
  • Boehringer Ingelheim
  • Merck
  • Novartis
  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • Asmacure
  • Astellas Pharma
  • BioMarck Pharmaceuticals
  • Chiesi Farmaceutici
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Innoviva
  • Invion
  • MediciNova
  • Mereo BioPharma
  • Mylan
  • Orion Corporation
  • Palobiofarma
  • Pearl Therapeutics
  • Pharmaxis
  • Prosonix
  • ZAI Lab

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Pipeline analysis

PART 06: Market landscape

PART 07: Key buying criteria for COPD drugs

PART 08: Market segmentation by drug class

PART 09: Segmentation by ROA

PART 10: Drug delivery devices market for COPD drugs

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

PART 18: Key vendor analysis

PART 19: Appendix

PART 20: About the Author

For more information visit http://www.researchandmarkets.com/research/c83czw/global_chronic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory Drugs